Opus Genetics Plans To Present Topline Clinical Data From Cohort 1 Of Its Phase 1/2 Study Of OPGx-BEST1 During Investor Conference Call And Webcast On September 9

Loading news article.

Opus Genetics Plans To Present Topline Clinical Data From Cohort 1 Of Its Phase 1/2 Study Of OPGx-BEST1 During Investor Conference Call And Webcast On September 9 | WAPE

Opus Genetics Plans To Present Topline Clinical Data From Cohort 1 Of Its Phase 1/2 Study Of OPGx-BEST1 During Investor Conference Call And Webcast On September 9

Article summary

Related companies

Analyzed by WAPE AI.

Comments —